Home
World Journal of Advanced Research and Reviews
International Journal with High Impact Factor for fast publication of Research and Review articles

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

eISSN: 2581-9615 || CODEN: WJARAI || Impact Factor 8.2 ||  CrossRef DOI

Research and review articles are invited for publication in March 2026 (Volume 29, Issue 3) Submit manuscript

Olaparib an anticancer drug: A review

Breadcrumb

  • Home
  • Olaparib an anticancer drug: A review

Rohit Deepak Nalawade * and Bhagwan Dilip Devkar

Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research, Chinchwad, Pune-411019, Maharashtra, India.
 
Review Article
World Journal of Advanced Research and Reviews, 2021, 11(02), 329-336
Article DOI: 10.30574/wjarr.2021.11.2.0406
DOI url: https://doi.org/10.30574/wjarr.2021.11.2.0406
Received on 21 July 2021; revised on 26 August 2021; accepted on 28 August 2021
 
Olaparib is an anti-cancer drug which comes under N-acyl piperazines class. The action of olaparib is PRPA inhibition. Drug taken by oral route which shows action in 1 to 3 hrs. after administration. It is FDA approved drug for various cancer treatment such as ovarian cancer, breast cancer, prostatic cancer and pancreatic cancer. Olaparib also useful different mutation conditions such as BRCA1/2 mutation. Olaparib prescribes after the chemotherapy treatment either singly or in combination. In serious and advanced mutation conditions combination therapy used. In this review paper, we put a narrative information about olaparib action, treatment approaches, pharmacokinetics, dosing regimen and resistance. Here we briefly give information about resistance mechanism of olaparib, treatment approaches in ovarian cancer, breast cancer and prostate cancer.
 
PRPA inhibition; BRCA mutation; Pharmacokinetic; Resistance; Dosing regimen
 
https://wjarr.com/sites/default/files/fulltext_pdf/WJARR-2021-0406.pdf

Preview Article PDF

Rohit Deepak Nalawade and Bhagwan Dilip Devkar. Olaparib an anticancer drug: A review. World Journal of Advanced Research and Reviews, 2021, 11(2), 329-336. Article DOI: https://doi.org/10.30574/wjarr.2021.11.2.0406

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.

All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 World Journal of Advanced Research and Reviews - All rights reserved

Developed & Designed by VS Infosolution